Drug Approvals Reach 15-Year High on Smoother FDA Reviews

U.S. drug approvals in 2012 reached their highest level in 15 years, led by 11 new cancer therapies, including Ariad Pharmaceuticals Inc.’s Iclusig and Pfizer Inc.’s Bosulif, both aimed at forms of leukemia.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.